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Abstract
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in 
the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel 
movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 
companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS 
(diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid 
(u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 
12-week double-blind treatment period followed by a 36-week open-label extension (OLE). 
The primary safety and efficacy endpoints were incidence of treatment-emergent adverse 
events (TEAEs) and percent change from baseline in 24-h u5-HIAA at week 12. Patients 
(N = 76) were randomly assigned (1:1:1) to receive placebo or telotristat ethyl 250 mg or 
500 mg 3 times per day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the 
OLE. Through week 12, TEAEs were generally mild to moderate in severity; 5 (placebo), 
1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg) patients experienced serious 
events, and the rate of TEAEs in the OLE was comparable. At week 12, significant reductions 
in u5-HIAA from baseline were observed, with Hodges–Lehmann estimators of median 
treatment differences from placebo of −54.0% (95% confidence limits, −85.0%, −25.1%, 
P < 0.001) and −89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat 
ethyl 250 mg and 500 mg. These results support the safety and efficacy of telotristat ethyl 
when added to SSAs in patients with CS diarrhea (ClinicalTrials.gov identifier: NCT02063659).
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Introduction
Carcinoid syndrome (CS) is a disorder that develops in up 
to 20% of patients with neuroendocrine tumors (NETs) and 
is characterized by severe diarrhea, flushing, abdominal 
pain, and eventually cardiac valvular complications, 
which can lead to heart failure (Fox & Khattar 2004, 
Mamikunian et  al. 2009, National Cancer Institute 
2015, Davar et  al. 2017, Halperin et  al. 2017, National 
Comprehensive Cancer Network 2017). Overproduction 
of serotonin by NETs results in elevated systemic levels of 
serotonin and can be measured by tracking the urinary 
metabolite 5-hydroxyindoleacetic acid (u5-HIAA). 
Elevated levels of serotonin occur mainly in metastatic 
disease and are associated with diarrhea, one of the 
most common symptoms of CS, and the development of 
carcinoid heart disease; further, high levels of u5-HIAA 
in patients with NETs have been associated with poor 
survival (Moertel 1987, van der Horst-Schrivers et al. 2007, 
Boudreaux et  al. 2010, National Cancer Institute 2015, 
National Comprehensive Cancer Network 2017).
Somatostatin analogs (SSAs), introduced in the mid-
1980s for the management of CS, are considered the 
standard of care for patients suffering from this condition 
(Boudreaux et al. 2010, Oberg & Lamberts 2016, National 
Comprehensive Cancer Network 2017, Pavel et al. 2017b). 
SSAs inhibit serotonin secretion and are an effective 
initial treatment for CS, but symptoms often reoccur 
over the course of the disease (Boudreaux et  al. 2010, 
Modlin et al. 2010).
Telotristat ethyl, previously referred to as the 
hippurate salt, telotristat etiprate, is an inhibitor of 
tryptophan hydroxylase, the rate-limiting enzyme in 
serotonin biosynthesis (Liu et al. 2008, Kulke et al. 2017). 
The phase 3 TELESTAR study demonstrated that treatment 
with telotristat ethyl was generally well tolerated and was 
associated with significant reductions in bowel movement 
(BM) frequency and u5-HIAA levels in patients with CS 
not adequately controlled by SSA therapy (≥4 BMs per day 
(BMs/day) while receiving SSAs). Of note, in studies with 
octreotide or lanreotide conducted prior to TELESTAR, 
control of u5-HIAA levels had been a challenge, and 
dose response had not been well characterized for 
u5-HIAA reduction (Kvols et al. 1986, Rubin et al. 1999, 
Ruszniewski et  al. 2004). Telotristat ethyl at a dosage of 
250 mg 3 times per day was recently approved by the 
US Food and Drug Administration and the European 
Commission and is a category 2A recommendation in the 
National Comprehensive Cancer Network clinical practice 
guidelines for the treatment of CS diarrhea inadequately 
controlled by SSA therapy (European Commission 2017, 
FDA News Release 2017, Lexicon Pharmaceuticals 2017, 
National Comprehensive Cancer Network 2017).
In this international, multicenter, randomized, 
double-blind, placebo-controlled phase 3 companion 
study, TELECAST, the safety and efficacy of telotristat 
ethyl were assessed in patients with symptomatic CS 
who either had <4 BMs/day with concomitant SSA 
therapy (meaning that increased BM frequency was not 
a primary CS symptom for these patients) or who were 
not receiving concomitant SSA therapy (ClinicalTrials.
gov identifier: NCT02063659). The present TELECAST 
study aims to complement the earlier TELESTAR study by 
providing information on the effects of telotristat ethyl 
in patients who did not qualify for TELESTAR, including 
patients who were experiencing <4 BMs/day but had 
other manifestations of CS such as elevated u5-HIAA or 
flushing. This report constitutes the first publication of the 
TELECAST results, which have previously been presented 
in part (Pavel et al. 2016, 2017a).
Materials and methods
Patients
Eligible patients were ≥18  years of age and had 
histopathologically confirmed, well-differentiated 
metastatic NETs with a documented history of CS. 
Patients receiving SSA therapy for the treatment of CS 
prior to the study were required to be on stable-dose 
SSAs (long-acting release, depot or infusion pump) for 
at least 3 months prior to enrollment, be experiencing 
an average of <4 BMs/day and have at least 1 of the 
following signs or symptoms: (1) daily stool consistency 
≥5 on the Bristol Stool Form scale (1 (hard lumps) to 
7  (watery liquid)) for ≥50% of the days during the 
run-in period (indicating that the patient had diarrhea 
or stools that were softer than normal) (Longstreth et al. 
2006); (2) average daily cutaneous flushing frequency 
of ≥2; (3) average daily rating of ≥3 for abdominal 
pain; (4) nausea present ≥20% of days or (5) u5-HIAA 
above the upper limit of normal (ULN). For patients not 
receiving SSA therapy, eligibility depended on having at 
least 1 of the above signs or symptoms or an average of 
≥4 BMs/day.
Patients were excluded if they met any of the 
following criteria: had diarrhea attributable to any 
condition other than CS; were experiencing ≥4 BMs/day 
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while on concomitant SSA therapy; showed evidence 
of enteric infection; had a Karnofsky performance 
status ≤60%; had a history of short bowel syndrome or 
chronic or idiopathic constipation; showed clinically 
important baseline elevation in liver function tests or 
had undergone tumor-directed therapy within 4  weeks 
prior to screening or hepatic embolization, radiotherapy, 
radiolabeled SSA therapy and/or tumor debulking within 
12 weeks prior to screening. Additional exclusion criteria 
are described in the Supplementary methods (see section 
on supplementary data given at the end of this article).
Study design and treatment
Patient baseline symptoms were established by a 
screening/run-in period of at least 3 weeks. Randomization 
was stratified by baseline u5-HIAA levels (categories 
of ≤ULN, >ULN, and unknown (missing at the time 
of randomization or uninterpretable)). Patients were 
randomly assigned 1:1:1 to receive oral doses of telotristat 
ethyl 250 mg or 500 mg 3 times per day (tid) or placebo 
tid during the double-blind treatment (DBT) period of 
12 weeks. Patients assigned to the telotristat ethyl 500 mg 
group underwent a blinded titration, receiving telotristat 
ethyl 250 mg tid for the first 7 days. Following the DBT 
period, patients could opt to continue treatment with 
telotristat ethyl 500 mg tid in a 36-week open-label 
extension (OLE) period. For patients treated with placebo 
during the DBT period, a blinded titration with telotristat 
ethyl 250 mg occurred during the initial 7-day OLE period, 
followed by an increase to telotristat ethyl 500 mg after 
7 days. Downward dose adjustment was allowed during 
the OLE in cases of intolerability. Rescue short-acting SSA 
use was allowed and unrestricted during the study, and 
patients continued to receive their baseline stable-dose 
SSA therapy.
The study protocol and amendments were approved by 
the institutional review board or ethics committee at each 
center, and the study was conducted in agreement with 
Good Clinical Practice guidelines and the Declaration of 
Helsinki. All patients provided written informed consent.
Efficacy and safety assessments
The primary safety and efficacy endpoints were the 
incidence of treatment-emergent adverse events (TEAEs) 
and percent change from baseline in 24-h u5-HIAA 
levels at week 12, respectively. Adverse events (AEs) were 
graded in severity by the investigator as mild, moderate 
or severe. Event severity grading is fully described in the 
Supplementary methods. Depression-related AEs were 
prespecified as AEs of special interest (AESIs). Although 
not defined as such in the protocol, gastrointestinal 
disorder AEs and hepatic-enzyme-related AEs were also 
considered AESIs based on clinical experience in phase 1 
and 2 studies. Planned efficacy analyses were based on the 
intent-to-treat population.
Key secondary efficacy endpoints included the change 
from baseline averaged over the 12-week DBT period for 
daily BM frequency, stool consistency, cutaneous flushing 
episodes, abdominal pain and frequency of rescue short-
acting SSA treatment. Additional analyses of efficacy 
endpoints included durability of response to treatment 
(a durable response was predefined in the statistical analysis 
plan as a ≥30% reduction in BM frequency for ≥50% of 
each patient’s days on treatment in the DBT period).
Patient-reported measures were collected via an 
electronic patient diary (eDiary), which was identical to 
the one used in the TELESTAR study (Kulke et al. 2017) and 
was completed for BMs/day, number of cutaneous flushing 
episodes, abdominal pain/discomfort, sensation/severity 
of nausea, stool form/consistency, urgency to defecate, 
subjective global assessment of symptoms associated with 
CS, adequate relief of gastrointestinal symptoms of CS 
and need for self-administered rescue short-acting SSA 
therapy to treat symptoms associated with CS.
Statistical analysis
Statistical analyses were performed using SAS statistical 
software (SAS Institute, Cary, NC, USA), version 9.3 
or higher for the efficacy endpoints. Statistical testing 
used a two-sided α-level set at 0.05 in determining the 
significance. A blocked 2-sample Wilcoxon rank-sum 
statistic (stratified by baseline u5-HIAA levels) was used 
to evaluate treatment group differences for the primary 
efficacy endpoint. The nonparametric Hodges–Lehmann 
estimator of the median paired treatment difference was 
used to describe the magnitude of treatment effect. Sample 
size was based on percent change from baseline in 24-h 
u5-HIAA levels at week 12. Sixteen patients per arm would 
enable a power of 80% to detect a difference in u5-HIAA 
levels, assuming the difference between the treatment 
groups was 40% and the common standard deviation was 
35%, leading to an effect size (mean/standard deviation) 
of 1.143. A target reduction of 40% was chosen to reduce 
the risk of capturing changes due to natural variability of 
u5-HIAA levels; this is higher than the threshold in prior 
studies with NETs in which secretory biomarker reduction 
of ≥30% has been used as a measure of treatment efficacy 
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(Kulke et al. 2017, Yao et al. 2011). The evaluation of the 
safety endpoint was qualitative, and no statistical analyses 
were performed. Full statistical methods are described in 
the Supplementary methods.
Results
Patient characteristics
From April 2014 to April 2015, 76 patients from 11 
countries were randomly assigned (1:1:1) to receive 
telotristat ethyl 250 mg tid, telotristat ethyl 500 mg tid 
or placebo tid (Fig.  1). The patient demographics and 
baseline characteristics are described in Table  1. They 
were well balanced across many of the characteristics (age, 
sex, ethnicity, race, weight, height, baseline body mass 
index, baseline u5-HIAA level); however, there were some 
exceptions with respect to differences in concomitant 
therapies. At baseline, mean BMs/day ranged from 2.2 to 
2.8, whereas mean u5-HIAA levels ranged from 66.0 mg to 
86.3 mg per 24 h. Across all study arms, at least 68.4% of 
patients had u5-HIAA levels greater than the ULN. Patients 
Excluded (n=18)
Not meeting inclusion/met exclusion criteria (n=11)
Declined to participate or withdrew consent (n=1)
Physician decision (n=1)
Compliance failure (n=3)
Death (n=0)
Unknown reasons (n=2)
Allocated to telotristat ethyl 500 mg tid (n=25)
Received allocated intervention (n=25)
Did not receive allocated intervention (n=0)
Completed the DBT period (n=22)
Discontinued intervention in DBT period (n=3)
Lost to follow-up (n=0)
Adverse event (n=0)
Physician decision (n=0)
Withdrawal of consent (n=3)
Analyzed (n=19)
Excluded from analysis (n=3)
u5-HIAA sample not collected or 
analyzed, or collected late (n=3)
Entered the OLE period (n=21)
Assessed for eligibility
(N=94)
Randomly allocated 1:1:1
(n=76; n random allocations)
Allocation (DBT)
Allocated to telotristat ethyl 250 mg tid (n=25)
Received allocated intervention (n=25)
Did not receive allocated intervention (n=0)
Follow-up
Completed the DBT period (n=22)
Discontinued intervention in DBT period (n=3)
Lost to follow-up (n=0)
Adverse event (n=2)
Physician decision (n=0)
Withdrawal of consent (n=1)
Analysis
Analyzed (n=17)
Excluded from analysis (n=5)
u5-HIAA sample not collected or 
analyzed, or collected late (n=5)
Allocation (OLE)
Entered the OLE period (n=22)
Completed the OLE period (n=19)
Discontinued intervention in the OLE period (n=3)
Lost to follow-up (n=0)
Adverse event (n=2)
Death (n=0)
Lack of efficacy (n=0)
Physician decision (n=0)
Withdrawal of consent (n=1)
Other (n=0)
All patients treated with
telotristat ethyl 500 mg tid
Completed the OLE period (n=13)
Discontinued intervention in the OLE period (n=8)
Lost to follow-up (n=0)
Adverse event (n=1)
Death (n=0)
Lack of efficacy (n=1)
Physician decision (n=1)
Withdrawal of consent (n=4)
Other (n=1)
Allocated to placebo (n=26)
Received allocated intervention (n=26)
Did not receive allocated intervention (n=0)
Completed the DBT period (n=24)
Discontinued intervention in DBT period (n=2)
Lost to follow-up (n=0)
Adverse event (n=1)
Physician decision (n=1)
Withdrawal of consent (n=0)
Analyzed (n=22)
Excluded from analysis (n=2)
u5-HIAA sample not collected or 
analyzed, or collected late (n=2)
Entered the OLE period (n=24)
Completed the OLE period (n=15)
Discontinued intervention in the OLE period (n=9)
Lost to follow-up (n=0)
Adverse event (n=4)
Death (n=0)
Lack of efficacy (n=0)
Physician decision (n=0)
Withdrawal of consent (n=4)
Other (n=1)
Enrollment
Figure 1
CONSORT diagram of the TELECAST clinical trial. Patient flow in the TELECAST study. DBT, double-blind treatment; OLE, open-label extension; tid, 
3 times per day.
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were diagnosed with a NET an average of 7.8 years prior to 
inclusion in this study (standard deviation (s.d.) 3.8 years; 
median 9.1  years; range 0.6–19.1  years). Approximately 
90% (n = 68) of patients had medical histories of 
gastrointestinal disorders, most commonly diarrhea; 58% 
(n = 44) had metabolic and nutrition disorders, which 
included vitamin deficiencies, electrolyte abnormalities 
and malnutrition; and 42% (n = 32) of patients had a 
history of cardiac disorders, which included carcinoid 
heart disease in 9, 6 and 5 patients on placebo, telotristat 
ethyl 250 mg and telotristat ethyl 500 mg, respectively.
Patient disposition
In this study, 26 patients received placebo, 25 patients 
received telotristat ethyl 250 mg tid and 25 patients 
received telotristat ethyl 500 mg tid in the DBT period 
(Fig. 1). A total of 68 patients completed the DBT period: 
22 patients per telotristat ethyl group (88.0%) and 24 
patients (92.3%) in the placebo group. The mean telotristat 
ethyl exposure time during the DBT period was 11.5 weeks 
(median 12.0  weeks). Mean compliance was 91.8% (s.d. 
12.1%) and 92.8% (s.d. 11.8%) for the telotristat ethyl 
250 mg and telotristat ethyl 500 mg groups, respectively, 
and 96.7% (s.d. 4.8%) for the placebo group. Reasons for 
withdrawal or discontinuation are shown in Fig. 1.
Of the 68 patients who completed the DBT period, 67 
were enrolled in the OLE period. Patients who entered the 
OLE period received a mean of 30.3 additional weeks of 
telotristat ethyl exposure (median 36.0 weeks) from week 
13 to week 48. More than half of patients who started the 
OLE period (47/67, 70.1%) completed the full OLE period, 
and compliance was 76.1%. The most common reasons 
for discontinuation in both the DBT and OLE periods 
were withdrawal of consent (n = 4 for DBT and n = 9 for 
OLE) and AEs (n = 3 for DBT and n = 7 for OLE).
Primary endpoint: safety
During the DBT period, the overall incidence of any 
TEAEs was similar among all groups (Table  2). During 
the DBT period, 5 patients (19.2%) in the placebo group 
experienced a serious adverse event (SAE), whereas only 
1 patient (4.0%) and 3 patients (12.0%) experienced a 
SAE in the telotristat ethyl 250 mg and telotristat ethyl 
500 mg groups, respectively. TEAEs that were considered 
‘treatment related’ by investigators occurred more 
frequently in the telotristat ethyl treatment groups 
compared with the placebo group. Across all 3 groups, 
there were no deaths during the DBT or OLE periods. Only 
3 patients discontinued the study drug during the DBT 
period because of a TEAE: 1 patient in the placebo group 
Table 1 Demographic and baseline characteristics of the patient population.
 
 
Patient characteristics
DBT OLE
Placebo (n = 26)
Telotristat ethyl  
250 mg tid (n = 25)
Telotristat ethyl  
500 mg tid (n = 25)
Telotristat ethyl  
500 mg tid (n = 67)
Mean age, years (s.d.) 62.2 (10.3) 63.6 (12.6) 62.7 (12.0) 63.3 (11.4)
Median age (range) 65.0 (41–78) 62.0 (38–84) 63.0 (35–83) 64.0 (35–84)
Male, n (%) 13 (50.0) 14 (56.0) 15 (60.0) 39 (58.2)
u5-HIAA at randomization, n (%)a
 ≤ULN 9 (34.6) 5 (20.0) 8 (32.0) 19 (28.4)
 >ULN 17 (65.4) 18 (72.0) 17 (68.0) 46 (68.7)
 Unknown 0 2 (8.0) 0 2 (3.0)
Mean u5-HIAA at baseline, mg/day (median) 82.0 (31.1) 86.3 (84.0) 66.0 (40.0) 78.2 (43.1)
Mean BM frequency, counts/day (s.d.)b 2.2 (0.7) 2.5 (1.2) 2.8 (1.6) 2.4 (1.1)
Averaging ≥1 BM/day at baseline, n (%) 25 (96.2) 24 (96.0) 24 (96.0) 64 (95.5)
Averaging ≥4 BMs/dayc at baseline, n (%) 0 1 (4.0) 4 (16.0) 3 (4.5)
Mean weekly stool consistency score (s.d.)b 5.0 (0.9) 5.1 (0.8) 5.3 (0.8) 5.1 (0.9)
Mean number of flushing episodes/day (s.d.)b 3.7 (4.1) 2.7 (3.7) 1.8 (2.2) 2.6 (3.1)
Mean weekly abdominal pain rating (s.d.)b 1.7 (1.7) 1.2 (1.5) 1.8 (1.7) 1.5 (1.7)
SSA therapy at study entry, n (%)
 Octreotide 12 (46.2) 17 (68.0) 16 (64.0) 40 (59.7)
 Lanreotide 14 (53.8) 5 (20) 3 (12.0) 20 (29.9)
 Unknown 0 0 1 (4.0) 1 (1.5)
 Not on SSA 0 3 (12.0) 5 (20.0) 6 (9.0)
aReference range: normal u5-HIAA ≤0–15 mg per 24 h (Tellez et al. 2013); bbaseline diary endpoints for placebo (n = 25) and OLE (n = 66); cthese patients 
were not currently receiving LAR/depot/infusion SSA therapy.
BM, bowel movement; DBT, double-blind treatment; OLE, open-label extension; s.d., standard deviation; SSA, somatostatin analog; tid, 3 times per day; 
u5-HIAA, urinary 5-hydroxyindoleacetic acid; ULN, upper limit of normal.
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(malignant neoplasm progression) and 2 patients in the 
telotristat ethyl 250 mg group (upper abdominal pain and 
diarrhea). Most TEAEs were rated as mild or moderate 
in severity and were most commonly gastrointestinal in 
nature (Tables 2 and 3).
During the OLE, the types of safety-related events, 
incidences of overall TEAEs and incidences of TEAEs 
leading to study discontinuation were similar to those 
in the DBT period, considering the increased exposure to 
telotristat ethyl. Crossover from placebo or telotristat ethyl 
250 mg to telotristat ethyl 500 mg in the OLE period did 
not affect the incidence of TEAEs. During the OLE period, 
only 2 patients required downward dose adjustment to 
250 mg telotristat ethyl tid. TEAEs were generally mild or 
moderate in intensity, with the most frequently reported 
incidence being gastrointestinal in nature, specifically 
nausea. Four patients had TEAEs that were reported as both 
severe and treatment related by the investigator (Table 2; 
1 patient each: acute myocardial infarction, constipation, 
a small intestinal hemorrhage and an increase in gamma-
glutamyl transferase (GGT)).
AEs of special interest included depression, 
gastrointestinal disorders and hepatic enzyme elevations 
(Table 4) based on mechanism of action or previous clinical 
experience with telotristat ethyl (Liu et  al. 2008, Kulke 
et al. 2017). There was no increase in depression-related 
AEs on telotristat ethyl compared with placebo, and no 
severe or serious cases in either the DBT or OLE period. 
Two patients suffered from AEs related to depression (both 
of moderate severity), leading to study discontinuation in 
the OLE period; both patients had underlying depression 
and were receiving antidepressant therapy at baseline.
AEs of special interest related to hepatic enzyme 
abnormalities were mostly mild or moderate in severity. 
Two events led to study discontinuation during the 
OLE period. One patient experienced elevated alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), 
aspartate aminotransferase (AST) and GGT. Telotristat 
ethyl was discontinued, and the patient’s hepatic enzymes 
normalized within 3  months. Another patient had an 
underlying condition of elevated GGT levels at baseline 
and throughout the course of the study. A follow-up 
visit during the OLE period found that GGT levels had 
increased approximately 6-fold above baseline, and 
telotristat ethyl was discontinued. During the DBT period, 
2 patients (1 in each telotristat ethyl group) experienced 
an increase in GGT, 1 patient in the telotristat ethyl 250 mg 
group experienced an increase in ALT and 1 patient in the 
telotristat ethyl 500 mg group experienced an abnormal 
liver function test; however, there were no associated 
increases in bilirubin.
Gastrointestinal disorders (diarrhea, nausea, 
constipation, abdominal pain, abdominal distension, 
dyspepsia, vomiting and abdominal discomfort) were 
frequent TEAEs for all groups in both the DBT and OLE 
periods; however, there was no dose-dependent or drug-
dependent relationship between telotristat ethyl and 
gastrointestinal symptoms. The most frequent severe 
TEAE observed in the DBT period (3 patients), abdominal 
pain, was seen in only 1 patient during the OLE period. 
Table 2 Number of patients with TEAEs reported in the DBT and OLE periods.
 
 
Category, n (%)
DBT OLE
Placebo (n = 26)
Telotristat ethyl  
250 mg tid (n = 25)
Telotristat ethyl  
500 mg tid (n = 25)
Telotristat ethyl  
500 mg tid (n = 67)
Any TEAE 21 (80.8) 25 (100.0) 22 (88.0) 61 (91.0)
TEAE by severitya
 Mild 9 (34.6) 9 (36.0) 10 (40.0) 11 (16.4)
 Moderate 11 (42.3) 13 (52.0) 11 (44.0) 30 (44.8)
 Severe 1 (3.8) 3 (12.0) 1 (4.0) 20 (29.9)
Treatment-related TEAEs 7 (26.9) 10 (40.0) 11 (44.0) 28 (41.8)
Serious TEAEsb 5 (19.2) 1 (4.0) 3 (12.0) 17 (25.4)
Treatment-related serious TEAEsc 0 0 0 2 (3.0)
Study discontinuation due to TEAEsd 1 (3.8) 2 (8.0) 0 7 (10.4)
TEAE resulting in death 0 0 0 0
aSeverity grades are defined in the Supplementary methods; patients with ≥1 TEAE in a given period are counted once at the maximum severity across 
all the patient’s TEAEs for that period; blife-threatening AE, death, hospitalization, persistent or significant incapacity or disruption of ability to conduct 
normal life functions, or congenital anomaly or birth defect; ctreatment-related serious TEAEs during the OLE period were acute myocardial infarction 
and small intestinal hemorrhage (1 patient each); dTEAEs leading to study discontinuation in the DBT period were upper abdominal pain, diarrhea, 
and tumor progression (1 patient each), and in the OLE period they were small intestinal hemorrhage, performance status decrease, elevated  
gamma-glutamyl transferase or hepatic enzymes, tumor progression (1 patient each), and depression (2 patients).
AE, adverse event; DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times per day.
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Table 3 Incidence of TEAEs in ≥5% of patients in any group.
 
 
System organ class preferred term, n (%)
DBT OLE
Placebo (n = 26)
Telotristat ethyl 
250 mg tid (n = 25)
Telotristat ethyl 
500 mg tid (n = 25)
Telotristat ethyl 
500 mg tid (n = 67)
Blood and lymphatic system disorders† 1 (3.8) 1 (4.0) 1 (4.0) 4 (6.0)
Anemia 0 1 (4.0) 1 (4.0) 4 (6.0)
Cardiac disorders† 2 (7.7) 0 0 12 (17.9)
Ear and labyrinth disorders† 0 0 0 4 (6.0)
Gastrointestinal disorders† 15 (57.7) 16 (64.0) 10 (40.0) 39 (58.2)
 Nausea 4 (15.4) 3 (12.0) 2 (8.0) 14 (20.9)
 Abdominal pain 4 (15.4) 8 (32.0) 1 (4.0) 12 (17.9)
 Diarrhea 5 (19.2) 4 (16.0) 2 (8.0) 9 (13.4)
 Constipation 1 (3.8) 4 (16.0) 3 (12.0) 8 (11.9)
 Vomiting 1 (3.8) 1 (4.0) 1 (4.0) 7 (10.4)
 Abdominal pain upper 3 (11.5) 1 (4.0) 2 (8.0) 5 (7.5)
 Abdominal distension 0 3 (12.0) 1 (4.0) 4 (6.0)
 Dyspepsia 2 (7.7) 2 (8.0) 0 0
General disorders and administration site conditions† 6 (23.1) 8 (32.0) 4 (16.0) 24 (35.8)
 Fatigue 2 (7.7) 3 (12.0) 2 (8.0) 7 (10.4)
 Pyrexia 0 3 (12.0) 0 6 (9.0)
 Asthenia 2 (7.7) 1 (4.0) 0 7 (10.4)
 Peripheral edema 0 2 (8.0) 1 (4.0) 5 (7.5)
Infections and infestations† 5 (19.2) 8 (32.0) 5 (20.0) 17 (25.4)
 Urinary tract infection 0 3 (12.0) 0 3 (4.5)
 Influenza 0 0 2 (8.0) 1 (1.5)
 Nasopharyngitis 1 (3.8) 1 (4.0) 0 5 (7.5)
Injury, poisoning, and procedural complications†,a 1 (3.8) 0 1 (4.0) 9 (13.4)
Investigations†,b 3 (11.5) 3 (12.0) 2 (8.0) 18 (26.9)
 Gamma-glutamyl transferase increase 0 1 (4.0) 1 (4.0) 4 (6.0)
 Weight decreased 0 1 (4.0) 0 4 (6.0)
Metabolism and nutrition disorders† 0 1 (4.0) 2 (8.0) 14 (20.9)
 Decreased appetite 0 0 2 (8.0) 6 (9.0)
Musculoskeletal and connective tissue disorders†,b 4 (15.4) 1 (4.0) 5 (20.0) 22 (32.8)
 Myalgia 2 (7.7) 1 (4.0) 1 (4.0) 2 (3.0)
 Musculoskeletal pain 0 0 2 (8.0) 2 (3.0)
 Arthralgia 1 (3.8) 0 0 4 (6.0)
 Back pain 1 (3.8) 0 0 5 (7.5)
Neoplasms benign, malignant, and unspecified 
(including cysts and polyps)†
1 (3.8) 1 (4.0) 4 (16.0) 5 (7.5)
Nervous system disorders† 5 (19.2) 2 (8.0) 3 (12.0) 16 (23.9)
 Dizziness 3 (11.5) 0 2 (8.0) 3 (4.5)
 Headache 1 (3.8) 0 1 (4.0) 5 (7.5)
 Presyncope 0 1 (4.0) 0 5 (7.5)
Psychiatric disorders†,b 2 (7.7) 2 (8.0) 2 (8.0) 16 (23.9)
 Depression 0 0 1 (4.0) 8 (11.9)
 Depressed mood 2 (7.7) 1 (4.0) 0 2 (3.0)
Renal and urinary disorders† 1 (3.8) 3 (12.0) 0 8 (11.9)
Respiratory, thoracic, and mediastinal disorders† 3 (11.5) 3 (12.0) 1 (4.0) 13 (19.4)
 Dyspnea 2 (7.7) 1 (4.0) 0 4 (6.0)
 Oropharyngeal pain 0 2 (8.0) 0 1 (1.5)
 Cough 0 1 (4.0) 0 4 (6.0)
Skin and subcutaneous tissue disorders† 1 (3.8) 6 (24.0) 3 (12.0) 10 (14.9)
 Night sweats 0 2 (8.0) 1 (4.0) 1 (1.5)
Surgical and medical procedures† 1 (3.8) 0 0 8 (11.9)
Vascular disorders† 4 (15.4) 5 (20.0) 2 (8.0) 15 (22.4)
 Flushing 2 (7.7) 3 (12.0) 0 9 (13.4)
†Subcategories experienced by <5% of patients are not included; apreferred terms included for injury, poisoning, and procedural complications are listed 
in the Supplementary methods. Each of these categories was experienced by <5% of patients; bpreferred terms also included for investigations, 
musculoskeletal and connective tissue disorders, and psychiatric disorders are listed in the Supplementary methods. Each of these categories was 
experienced by <5% of patients.
DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times per day.
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Table 4 Adverse events of special interest.
 
 
AESI category preferred term, n (%)
DBT OLE
 
Placebo tid (n = 26)
Telotristat ethyl 
250 mg tid (n = 25)
Telotristat ethyl 
500 mg tid (n = 25)
 Telotristat ethyl 
500 mg tid (n = 67)
Gastrointestinal-related TEAE
 Abdominal pain Total 4 (15.4) 8 (32.0) 1 (4.0) 12 (17.9)
Mild 1 (3.8) 3 (12.0) 0 5 (7.5)
Moderate 3 (11.5) 3 (12.0) 0 6 (9.0)
Severe 0 2 (8.0) 1 (4.0) 1 (1.5)
 Diarrhea Total 5 (19.2) 4 (16.0) 2 (8.0) 9 (13.4)
Mild 2 (7.7) 2 (8.0) 1 (4.0) 3 (4.5)
Moderate 3 (11.5) 2 (8.0) 1 (4.0) 4 (6.0)
Severe 0 0 0 2 (3.0)
 Nausea Total 4 (15.4) 3 (12.0) 2 (8.0) 14 (20.9)
Mild 4 (15.4) 2 (8.0) 2 (8.0) 8 (11.9)
Moderate 0 1 (4.0) 0 5 (7.5)
Severe 0 0 0 1 (1.5)
 Constipation Total 1 (3.8) 4 (16.0) 3 (12.0) 8 (11.9)
Mild 0 3 (12.0) 3 (12.0) 5 (7.5)
Moderate 1 (3.8) 1 (4.0) 0 2 (3.0)
Severe 0 0 0 1 (1.5)
 Abdominal pain upper Total 3 (11.5) 1 (4.0) 2 (8.0) 5 (7.5)
Mild 2 (7.7) 0 2 (8.0) 3 (4.5)
Moderate 1 (3.8) 1 (4.0) 0 2 (3.0)
Severe 0 0 0 0
 Abdominal distension Total 0 3 (12.0) 1 (4.0) 4 (6.0)
Mild 0 2 (8.0) 1 (4.0) 4 (6.0)
Moderate 0 1 (4.0) 0 0
Severe 0 0 0 0
 Abdominal discomfort Total 1 (3.8) 0 1 (4.0) 1 (1.5)
Mild 1 (3.8) 0 1 (4.0) 1 (1.5)
Moderate 0 0 0 0
Severe 0 0 0 0
 Flatulence Total 0 1 (4.0) 1 (4.0) 2 (3.0)
Mild 0 1 (4.0) 1 (4.0) 1 (1.5)
Moderate 0 0 0 1 (1.5)
Severe 0 0 0 0
 Abdominal tenderness Total 0 0 1 (4.0) 0
Mild 0 0 1 (4.0) 0
Moderate 0 0 0 0
Severe 0 0 0 0
 Frequent bowel movements Total 0 1 (4.0) 0 0
Mild 0 0 0 0
Moderate 0 1 (4.0) 0 0
Severe 0 0 0 0
 Abdominal pain lower Total 0 0 0 1 (1.5)
Mild 0 0 0 0
Moderate 0 0 0 1 (1.5)
Severe 0 0 0 0
 Gastrointestinal pain Total 0 0 0 1 (1.5)
Mild 0 0 0 1 (1.5)
Moderate 0 0 0 0
Severe 0 0 0 0
 Vomiting Total 1 (3.8) 1 (4.0) 1 (4.0) 7 (10.4)
Mild 0 1 (4.0) 0 4 (6.0)
Moderate 1 (3.8) 0 1 (4.0) 2 (3.0)
Severe 0 0 0 1 (1.5)
(Continued)
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Constipation was reported more often on telotristat ethyl 
than placebo. Constipation was rated as mild to moderate 
in 7 of the 8 patients reporting this event during the OLE 
period. Nausea occurred with similar frequencies among 
patients treated with placebo and telotristat ethyl during 
the DBT period and did not result in SAEs or treatment 
discontinuation.
There were no significant changes in vital signs 
(other than weight), electrocardiogram measurements 
or physical examination findings during the DBT period. 
With respect to weight, 2 (8.7%), 4 (17.4%) and 5 (20.8%) 
patients in the placebo, telotristat ethyl 250 mg and the 
telotristat ethyl 500 mg groups, respectively, had at least 
a 3% gain in body weight during the DBT period. The 3 
patients with electrocardiogram changes outside of the 
normal range were on placebo, and 2 had underlying 
histories of cardiac disorders. Electrocardiogram measures 
included heart rate, PR duration, QRS duration and QT 
interval and are summarized in Supplementary Table 1.
Primary endpoint: efficacy
A statistically significant reduction from baseline in 
u5-HIAA levels was observed at week 12 for both the 
 
 
AESI category preferred term, n (%)
DBT OLE
 
Placebo tid (n = 26)
Telotristat ethyl 
250 mg tid (n = 25)
Telotristat ethyl 
500 mg tid (n = 25)
 Telotristat ethyl 
500 mg tid (n = 67)
Depression-related TEAE
 Depressed mood Total 2 (7.7) 1 (4.0) 0 2 (3.0)
Mild 2 (7.7) 1 (4.0) 0 2 (3.0)
Moderate 0 0 0 0
Severe 0 0 0 0
 Decreased interest Total 1 (3.8) 0 0 0
Mild 1 (3.8) 0 0 0
Moderate 0 0 0 0
Severe 0 0 0 0
 Depression Total 0 0 1 (4.0) 8 (11.9)
Mild 0 0 0 4 (6.0)
Moderate 0 0 1 (4.0) 4 (6.0)
Severe 0 0 0 0
Hepatic-enzyme-related TEAE
Elevated gamma-glutamyl 
transferase
Total 0 1 (4.0) 1 (4.0) 4 (6.0)
Mild 0 1 (4.0) 0 1 (1.5)
Moderate 0 0 1 (4.0) 1 (1.5)
Severe 0 0 0 2 (3.0)
Elevated alanine 
aminotransferase
Total 0 1 (4.0) 0 3 (4.5)
Mild 0 1 (4.0) 0 2 (3.0)
Moderate 0 0 0 0
Severe 0 0 0 1 (1.5)
 Liver function test abnormal Total 0 0 1 (4.0) 1 (1.5)
Mild 0 0 1 (4.0) 0
Moderate 0 0 0 1 (1.5)
Severe 0 0 0 0
Elevated aspartate 
aminotransferase
Total 0 0 0 3 (4.5)
Mild 0 0 0 2 (3.0)
Moderate 0 0 0 0
Severe 0 0 0 1 (1.5)
Blood alkaline phosphatase 
increased
Total 0 0 0 2 (3.0)
Mild 0 0 0 1 (1.5)
Moderate 0 0 0 1 (1.5)
Severe 0 0 0 0
 Hepatic enzyme increased 
 
 
Total 0 0 0 2 (3.0)
Mild 0 0 0 1 (1.5)
Moderate 0 0 0 1 (1.5)
Severe 0 0 0 0
AESI, adverse event of special interest; DBT, double-blind treatment; OLE, open-label extension; TEAE, treatment-emergent adverse event; tid, 3 times 
per day.
Table 4 Continued.
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telotristat ethyl 250 mg and telotristat ethyl 500 mg 
groups compared with the placebo group (P < 0.001 for 
each comparison) and continued through the OLE period 
for the majority of patients (Fig.  2). Baseline and week 
12 values were available for 17, 19 and 22 patients in 
the telotristat ethyl 250 mg, telotristat ethyl 500 mg and 
placebo groups, respectively. Ten patients who completed 
the DBT period were excluded from the primary efficacy 
analysis because of deviations related to u5-HIAA sample 
collection or analysis. At week 12, significant reductions in 
u5-HIAA levels from baseline were observed with Hodges–
Lehmann estimator of treatment differences from placebo 
of −54.0% (95% confidence limits (CL) −85.0%, −25.1%) 
for the 250 mg telotristat ethyl group and −89.7% (95% 
CL −113.1%, −63.9%) for the 500 mg telotristat ethyl 
group (P < 0.001 for both vs placebo). Additionally, more 
patients in the telotristat ethyl groups demonstrated a 
reduction in u5-HIAA levels at week 12 compared with 
the placebo group (15 of 17 patients for telotristat ethyl 
250 mg, 19 of 19 patients for telotristat ethyl 500 mg and 
8 of 22 patients for placebo).
Additional efficacy endpoints
Treatment with telotristat ethyl at either dosage was also 
associated with statistically significant reductions in BMs/
day averaged over the 12-week DBT period compared 
with placebo (P = 0.004 for telotristat ethyl 250 mg and 
P < 0.001 for telotristat ethyl 500 mg, Table  5; percent 
change in BM frequency from baseline per week is shown 
in Fig. 3). The Hodges–Lehmann estimator of treatment 
difference from placebo for patients receiving telotristat 
ethyl was −0.45 for the telotristat ethyl 250 mg group 
and −0.54 for the telotristat ethyl 500 mg group. Durable 
responses (predefined in the statistical analysis plan as 
responders with ≥30% reduction in daily number of BMs 
for ≥50% of the time over the DBT period) were observed 
only in patients on telotristat ethyl. Ten patients in each 
telotristat ethyl group (40.0%) were classified as durable 
responders, whereas none of the patients who received 
placebo were classified as durable responders (treatment 
difference in responder rate of 0.40; 95% CL 0.17, 0.63; 
P = 0.001). During the DBT period, a mean reduction in BM 
frequency by approximately 1 BM/day was also observed 
in the small number (n = 8) of telotristat ethyl–treated 
patients who were not on concurrent SSA therapy. The 
mean reduction in BMs/day observed in the DBT period 
for telotristat ethyl–treated patients continued through 
the OLE period.
Telotristat ethyl 500 mg had a statistically significant 
(P = 0.009) effect on stool form/consistency, as measured 
by the Bristol Stool Form scale, compared with placebo 
during the DBT period. From the Hodges–Lehmann 
estimator, there was a difference of −0.39 (95% CL −0.82, 
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Telotristat ethyl 250 mg tid (n=17)
Figure 2
Changes in u5-HIAA levels from baseline. (A) The Hodges–Lehmann (HL) 
estimator, a nonparametric measure used to describe the magnitude of 
treatment effect, was assessed at week 12 (aP < 0.001). bData include 1 
patient who experienced a 1864.5% increase from baseline. cThe colors 
and shapes in each bar represent the assigned treatment group during 
the double-blind treatment (DBT) period; clear bars with filled shapes 
indicate treatment of these patients with telotristat ethyl 500 mg 3 times 
per day (tid) during the open-label extension (OLE) period. (B) The 
distribution of individual patient responses to treatment with telotristat 
ethyl 250 mg tid or placebo, as percent change from baseline at week 12. 
One patient treated with placebo had a 1864.5% change from baseline 
and is not included in the figure. (C) The distribution of individual patient 
responses to treatment with telotristat ethyl 500 mg tid or placebo, as 
percent change from baseline at week 12. One patient treated with 
placebo had a 1864.5% change from baseline and is not included in the 
figure. u5-HIAA, urinary 5-hydroxyindoleacetic acid.
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−0.12). There was no statistically significant difference 
between the telotristat ethyl 250 mg group and the placebo 
group (P = 0.09), with the Hodges–Lehmann estimator at 
−0.20 (95% CL −0.45, 0.02).
During the DBT period, there were no statistically 
significant changes in cutaneous flushing, abdominal 
pain or frequency of rescue SSA therapy to treat CS 
symptoms. There was also no trend in the change from 
baseline in the number of rescue short-acting SSAs used 
to treat bowel-related CS symptoms across all time points 
in the DBT period, with mean changes of −0.01 counts 
per day (s.d. 0.14), −0.07 (s.d. 0.35) and 0.01 (s.d. 0.10) 
for placebo, telotristat ethyl 250 mg and telotristat ethyl 
500 mg, respectively.
Table 5 Secondary endpoints of the double-blind treatment period.
 
 
Variable
Placebo 
(n = 25)
Telotristat ethyl
250 mg tid (n = 25) 500 mg tid (n = 25)
Mean (s.d.) Mean (s.d.) P 95% CL Mean (s.d.) P 95% CL
BM frequency
Change from baseline in 
BM frequency averaged 
over 12 weeks, counts/day
0.05 (0.33) −0.45 (0.69) − − −0.60 (0.72) − −
Arithmetic mean 
treatment difference
− −0.50 − −0.81 to −0.19 −0.65 − −0.96 to −0.33
Hodges–Lehmann 
estimator
− −0.45 0.004 −0.72 to −0.17 −0.54 <0.001 −0.79 to −0.25
Stool consistency
Change from baseline in 
stool consistency 
averaged over 12 weeks 
(Bristol Stool Form scale)
0.01 (0.41) −0.20 (0.70) – – −0.60 (0.86) – –
Arithmetic mean 
treatment difference
− −0.20 – −0.53 to 0.13 −0.60 – −0.99 to −0.22
Hodges–Lehmann 
estimator
− −0.20 0.09 −0.45 to 0.02 −0.39 0.009 −0.82 to −0.12
Flushing
Change from baseline in 
daily cutaneous flushing 
episodes averaged over 
12 weeks, counts/day
−0.33 (1.22) −0.06 (0.98) – – 0.11 (2.10) – –
Arithmetic mean 
treatment difference
− 0.27 – −0.36 to 0.90 0.45 – −0.53 to 1.42
Hodges–Lehmann 
estimator
− 0.11 0.67 −0.17 to 0.61 0.02 0.58 −0.28 to 0.62
Abdominal pain
Change from baseline in 
abdominal pain 
averaged over 12 weeks, 
11-point numeric rating 
scale
−0.06 (0.78) −0.23 (0.97) – – 0.03 (0.77) – –
Arithmetic mean 
treatment difference
− −0.17 – −0.67 to 0.33 0.09 – −0.35 to 0.53
Hodges–Lehmann 
estimator
− 0.06 0.61 −0.42 to 0.33 0.14 0.66 −0.39 to 0.51
Rescue short-acting SSA use
Change from baseline in 
rescue short-acting SSA 
use averaged over 
12 weeks, counts/day
−0.01 (0.14) −0.07 (0.35) – – 0.01 (0.10) – –
Arithmetic mean 
treatment difference
− −0.05 – −0.20 to 0.10 0.02 – −0.05 to 0.09
Hodges–Lehmann 
estimator
− 0.00 0.45 0.00–0.00 0.000 0.98 0.00–0.00 
BM, bowel movement; CL, confidence limits; s.d., standard deviation; SSA, somatostatin analog; tid, 3 times per day.
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Discussion
There is a substantial need for safe and effective treatment 
to supplement the current standard of care of SSA therapy 
for the management of CS including diarrhea. Toward 
this end, this study met both primary safety and efficacy 
endpoints in the 12-week DBT period comparing 2 dosing 
regimens of telotristat ethyl vs placebo. During both the 
12-week DBT period and the OLE period of up to 36 weeks, 
treatment with telotristat ethyl was well tolerated, as 
indicated by the rarity of SAEs or discontinuations due 
to AEs. Overall, TEAEs and discontinuations due to TEAEs 
were similar among all treatment groups.
Notably, patients in this study had considerable 
comorbidities associated with metastatic NETs, such as 
gastrointestinal symptoms (most commonly diarrhea), 
metabolic and nutrition disorders and cardiac disorders, 
and patients were an average of 7.8  years since their 
diagnosis of a NET at inclusion in this study. Despite 
these comorbidities and the length of follow-up, there 
were no deaths during the DBT or OLE period, and more 
SAEs occurred in the placebo group compared with the 
telotristat ethyl groups during the DBT period.
The results for depression-related AEs were favorable 
compared with those reported in the phase 3 TELESTAR 
study. Previously, there has been a concern about 
depression with telotristat ethyl because of the known 
role of serotonin in depression; the pharmacologic 
profiles of earlier tryptophan hydroxylase inhibitors, 
which crossed the blood–brain barrier; and the reported 
numerically higher incidence of depression on telotristat 
ethyl 500 mg tid than on telotristat ethyl 250 mg tid or 
placebo during the TELESTAR study (Kulke et  al. 2017). 
As reported here in the TELECAST study, during the DBT 
period, depression-related AEs were reported more often 
on placebo (2 patients) compared with either dosage 
of telotristat ethyl (1 patient in each treatment group) 
during the DBT period. During the OLE period, depression 
led to discontinuation of therapy in 2 patients. Overall, in 
TELECAST, there was no imbalance in depression-related 
AEs during the DBT period. The slightly higher incidence 
of depression observed with telotristat ethyl 500 mg tid in 
the OLE period (11.9%) compared with the same dosage 
during the DBT period (4%) suggests that the emergence of 
depression could be time dependent. However, telotristat 
ethyl is unlikely to cross the blood–brain barrier (Liu et al. 
2008, Lapuerta et al. 2015), and the depression observed 
in TELESTAR and TELECAST might be related to the 
underlying disease or other causes; nevertheless, patients 
should be monitored for the occurrence of depression or 
depressed mood.
Consistent with the results of the TELESTAR study, 
elevations in hepatic enzymes appeared to be associated 
with telotristat ethyl (Kulke et al. 2017). Elevated hepatic 
enzymes (primarily GGT, with some elevations in ALT, AST 
and ALP) were observed in some patients, but there were 
no reported cases with clinically significant outcomes and 
no cases of coincident substantial increases in bilirubin.
Constipation also appeared to be drug related, 
and this is consistent with the mechanism of action of 
telotristat ethyl. In this study, most constipation-related 
AEs were mild to moderate in severity and resulted in no 
discontinuations of the study drug. However, symptoms 
of severe constipation or severe, persistent or worsening 
abdominal pain should be watched for, and if observed, 
telotristat ethyl should be discontinued to minimize the 
risk of possible complications.
A significant (P < 0.001) reduction in u5-HIAA levels 
was observed compared with baseline in patients given 
telotristat ethyl vs placebo during the 12-week DBT 
period. This reduction persisted during the OLE period. 
Elevated levels of u5-HIAA in patients with CS have been 
Figure 3
Mean changes from baseline (B) in frequency of 
bowel movements per day. The change in mean 
daily bowel movement (BM) frequency was 
assessed weekly over the double-blind treatment 
(DBT) and open-label extension (OLE) periods of 
the study. The dotted lines indicate the crossover 
of patients from either placebo or telotristat 
ethyl 250 mg 3 times per day (tid) to telotristat 
ethyl 500 mg tid in the OLE period.
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associated with valvular heart disease, mesenteric fibrosis 
and poor long-term survival (van der Horst-Schrivers et al. 
2007, Druce et  al. 2009, Davar et  al. 2017). Telotristat 
ethyl also significantly reduced BM frequency compared 
with placebo and produced a durable reduction in BM 
frequency in 40% of patients, similar to the results of 
the TELESTAR study (Kulke et  al. 2017). BM frequency 
for patients not on SSA therapy also improved; however, 
the small number of patients not on SSAs and the lack of 
patients in this category who were randomly assigned to 
receive placebo limit definitive conclusions. The weight 
increase observed in some patients in the telotristat ethyl 
groups could be the result of diarrhea control leading to 
better nutritional status.
The effects of telotristat ethyl on u5-HIAA and the 
BM symptoms associated with production of serotonin 
by NETs are consistent with results from previous 
studies and with telotristat ethyl’s selective inhibition of 
intratumoral serotonin production (Kulke et  al. 2017). 
Whereas the phase 3 TELESTAR study demonstrated the 
effect of telotristat ethyl in patients with CS diarrhea with 
≥4 BMs/day, this study showed a statistically significant 
effect on u5-HIAA levels and BMs/day in patients with less 
frequent BMs and elevated u5-HIAA.
In conclusion, treatment with telotristat ethyl for 
up to 48  weeks had a favorable safety profile, was well 
tolerated and was associated with sustained reductions 
in u5-HIAA and BM frequency. Data from this study and 
from the previous phase 3 TELESTAR study support the 
use of telotristat ethyl as an addition to SSAs in patients 
with CS diarrhea.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
ERC-17-0455.
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